Abstract
Epithelial ovarian cancer will strike between 1 - 2% of women in developed countries and, unfortunately, it largely remains a lethal disease due to late-stage at diagnosis and the eventual development of chemotherapy resistance. Ovarian cancer is initially treated with surgical resection and chemotherapy (primarily platinum/taxane combinations) and remission can be attained for the majority of patients. Despite this, most women will recur and require multiple further therapies. The purpose of this paper is to review the existing treatment options, including surgery, traditional chemotherapy as well as upcoming novel and targeted therapies that may one day improve outcomes in this disease.
Original language | English (US) |
---|---|
Pages (from-to) | 2293-2305 |
Number of pages | 13 |
Journal | Expert opinion on pharmacotherapy |
Volume | 8 |
Issue number | 14 |
DOIs | |
State | Published - Oct 2007 |
Externally published | Yes |
Keywords
- Ovarian cancer
- Platinum
- Recurrence
- Secondary debulking
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)